Efficacy and Tolerability of First-Line Anti-eGFR and Anti-VEGF Therapy in Elderly Patients with Ras-Wild Metastatic Colon Cancer

Author:

Doğan Ender,Fırat Sedat Tarık,Eser Murat,Bozkurt Oktay,İnanç Mevlüde,Özkan Metin

Publisher

Galenos Yayinevi

Reference15 articles.

1. 1. National Cancer Institute. SEER cancer statictics. review 1975-2001. Available at:http://seer.cancer.gov/csr/1975-2001

2. Colorectal cancer in elderly patients with surgical indication: state of the art, current management, role of frailty and benefits of a geriatric liaison;González-Senac;Int J Environ Res Public Health,2021

3. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD);Sastre;Crit Rev Oncol Hematol,2011

4. 4. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995; 1: 1311-8.

5. Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: challenging drug label to light up new hope;Pietrantonio;Oncologist,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3